Short answer
Taysha Gene Therapies, Inc. (TSHA) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 furnished an 8-K and Exhibit 99.1, but the provided text contains no earnings figures or reporting-period results.
Taysha Gene Therapies, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 furnished an 8-K and Exhibit 99.1, but the provided text contains no earnings figures or reporting-period results
- Information is not deemed filed under Exchange Act Section 18, limiting associated liability and incorporation by referenceWinvalid
Item EX-99.1 · Exhibit EX-99.1
- REVEAL pivotal dosing completed at 17 patients; six-month interim data and FDA BLA-pathway feedback expected in 1H 2027
- TSHA-102 safety remains favorable across 33 treated patients, with no severe treatment-related SAEs or DLTs as of August 2026
- Longer-term data showed broad functional gains deepening through ≥12 months, supporting potential durability but requiring pivotal confirmation
- $230 million follow-on offering lifted cash to $455.4 million and extended runway into 2H 2028, reducing near-term financing risk
- Quarterly net loss widened to $46.6 million, with R&D expense rising to $38.6 million amid clinical and BLA-enabling manufacturing spending
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Taysha Gene Therapies, Inc. 8-K filings
Get the next TSHA 8-K as it lands
Follow TSHA for push alerts, or ask the research agent what this filing means.